80
Participants
Start Date
February 16, 2022
Primary Completion Date
November 7, 2022
Study Completion Date
November 21, 2022
BAY2395840
Tablet, intake orally.
Placebo for BAY2395840
Tablet, intake orally.
Clinexpert Kft., Budapest
Coromed Smo Kft, Pécs
DRC Gyogyszervizsgalo Kozpont Kft., Balatonfüred
Klinische Forschung Berlin GbR, Berlin
Vseobecna fakultni nemocnice v Praze, Prague
Klinische Forschung Schwerin GmbH, Schwerin
Klinische Forschung Hannover-Mitte GmbH, Hanover
Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW), Bad Oeynhausen
InnoDiab Forschung GmbH, Essen
Klinische Forschung Karlsruhe GmbH, Karlsruhe
NEUROHK s.r.o, Choceň
Interni a diabetologicka ambulance - Krnov, Krnov
Fakultni nemocnice Ostrava, Ostrava
Praglandia, Prague
Vestra Clinics s.r.o., Rychnov nad Kněžnou
Diabetologicka ambulance Vlasim, Vlašim
ALIAN s.r.o., Bardejov
NEUROPOINT sro, Neurologicka ambulancia, Bratislava
"Internal and Diabetes Clinic - IN-DIA s.r.o. , Lucenec, Slovakia"
"Hospital Gregorio Maranon , Endocrinology Department"
MAC Research Centre - Manchester, Manchester
Vseobecna nemocnica v Ziari nad Hronom, Žiar nad Hronom
Neuron - D.T. sro, Neurologicka ambulancia, Žilina
Medivasa s.r.o., Žilina
"Gerencia de Gestion Integrada A Coruna , Department of Endocrinology and Nutrition"
"Complexo HU Ferrol , Endocrinología y Nutrición"
"Hospital Univ. Bellvitge , Anestesiología y Unidad del Dolor"
Hospital General Universitario de Alicante, Alicante
MAC Clinical Research - Teesside, Teesside
King's College Hospital - NHS Foundation Trust, London
Lead Sponsor
Bayer
INDUSTRY